Order Article Reprints

Ntafoulis I, Koolen SLW, van Tellingen O, den Hollander CWJ, Sabel-Goedknegt H, Dijkhuizen S, Haeck J, Reuvers TGA, de Bruijn P, van den Bosch TPP, et al. A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma. Pharmaceuticals. 2024; 17(12):1687. https://doi.org/10.3390/ph17121687

Ntafoulis, Ioannis, Stijn L. W. Koolen, Olaf van Tellingen, Chelsea W. J. den Hollander, Hendrika Sabel-Goedknegt, Stephanie Dijkhuizen, Joost Haeck, Thom G. A. Reuvers, Peter de Bruijn, Thierry P. P. van den Bosch, and et al. 2024. "A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma" Pharmaceuticals 17, no. 12: 1687. https://doi.org/10.3390/ph17121687

Ntafoulis, I., Koolen, S. L. W., van Tellingen, O., den Hollander, C. W. J., Sabel-Goedknegt, H., Dijkhuizen, S., Haeck, J., Reuvers, T. G. A., de Bruijn, P., van den Bosch, T. P. P., van Dis, V., Gao, Z., Dirven, C. M. F., Leenstra, S., & Lamfers, M. L. M. (2024). A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma. Pharmaceuticals, 17(12), 1687. https://doi.org/10.3390/ph17121687